Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

20246 citationsJournal Articlegold Open Access

Authors

NCT05054348.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 12, Issue 11, pp. e010006-e010006

Field-Weighted Citation Impact: 1.46